Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Annexon, Inc. reported that it has updated its corporate investor presentation to reflect certain business and strategic updates. The revised presentation, dated January 14, 2026, may be used in upcoming meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference. It will also be available in the Investors & Media section of the company's website.
The investor presentation is furnished as Exhibit 99.1 under Item 7.01 and is expressly stated as being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other Securities and Exchange Commission documents.
Annexon, Inc. reported that it issued a press release outlining its 2026 strategic priorities and key milestones for its lead programs. The press release, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026,” focuses on advancing its next-generation targeted immunotherapy platform for neuroinflammatory diseases and highlights multiple planned registrational milestones in 2026. The full details are provided in the press release attached as Exhibit 99.1 to this report.
Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.
After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.
Annexon, Inc. (ANNX)Muneer A. Satter through affiliated entities. On November 20, 2025, Alerce Medical Technology Partners, L.P. bought 400,000 shares of common stock at a weighted average price of $4.48. On November 21, 2025, Alerce Medical purchased an additional 422,613 shares at a weighted average price of $4.28. After these transactions, Satter is reported as beneficially owning 9,728,637 shares, held indirectly through a revocable trust, other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Annexon, Inc. (ANNX) director reports sizable insider stock purchases. Over three consecutive days in November 2025, the reporting person, through Alerce Medical Technology Partners, L.P., bought 500,000 Annexon common shares on each of 11/17, 11/18, and 11/19.
The weighted average purchase prices were reported as $2.99, $3.18, and $3.94 for each respective day, with trades executed within stated price ranges. After these transactions, the reporting person beneficially owned 8,906,024 shares indirectly, including shares held in a revocable trust, various other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, subject to stated pecuniary interests.
Annexon, Inc. launched a primary offering of 25,096,153 shares of common stock and pre-funded warrants to purchase up to 3,750,000 shares, together with the shares issuable upon warrant exercise. The offering prices are $2.60 per share and $2.599 per pre-funded warrant, for gross proceeds of $74,996,247.80 and estimated net proceeds of about $69.9 million after fees and expenses.
The underwriters have a 30‑day option to buy up to 4,326,922 additional shares. Annexon plans to use proceeds to advance late‑stage programs, including tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and general corporate purposes.
Pre-funded warrants have a $0.001 exercise price, do not expire, and include a 9.99% beneficial ownership limit (adjustable up to 19.99% with notice). Shares outstanding were 115,122,582 as of September 30, 2025, and are expected to be 140,218,735 immediately after this offering, assuming no exercise of pre-funded warrants.
Annexon, Inc. (ANNX) announced a primary offering of $75,000,000 of common stock, with the option for certain investors to purchase pre-funded warrants instead. The company also registered the shares issuable upon exercise of the pre-funded warrants. Underwriters have a 30‑day option to buy up to an additional $11,250,000 of common stock.
Pre-funded warrants will be sold at the share offering price minus $0.001 and have a $0.001 per share exercise price, are exercisable immediately, do not expire, and include a 9.99% Beneficial Ownership Limitation (adjustable up to 19.99% with 61 days’ notice). Annexon’s common stock trades on the Nasdaq Global Select Market under “ANNX”; the last reported sale price was $2.97 on November 11, 2025. Shares outstanding were 115,122,582 as of September 30, 2025; this is a baseline figure, not the amount being offered.
The company intends to use proceeds to advance its late‑stage neuroinflammation platform, led by global registrational programs tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and other general corporate purposes. A 60‑day lock‑up applies, and sales under the existing 2024 ATM program are paused during this period.
Annexon, Inc. reported Q3 2025 results with a net loss of
Cash, cash equivalents and short‑term investments were
R&D increased as the company advanced tanruprubart (GBS) toward MAA/BLA packages and continued the vonaprument (GA) Phase 3 ARCHER II trial. The company raised
Annexon, Inc. (ANNX) furnished an update on its business by announcing certain financial results for the third quarter ended September 30, 2025. The company provided these details in a press release titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones,” attached as Exhibit 99.1.
The information was furnished under Item 2.02 of a Form 8‑K and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless specifically noted.
Annexon (ANNX) filed a Form 4 reporting an insider purchase by a director. On 10/30/2025, the director bought 4,115 shares of common stock at a $3.17 weighted average price, with individual trades executed between $3.15 and $3.20. The transaction was made under a Rule 10b5-1 trading plan adopted on March 17, 2025. Following the trade, the director beneficially owns 46,175 shares, held directly.